FDA Oncology Announcements

KRAS inhibitor × Clear all

4 Announcements

FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Trial: CodeBreak300
Drugs: Lumakras (sotorasib) · KRAS inhibitor, Vectibix (panitumumab) · Anti-EGFR antibody
Condition: Gastrointestinal

FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer

Drugs: Krazati (adagrasib) · KRAS inhibitor, cetuximab · Anti-EGFR antibody
Condition: Gastrointestinal

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

Drug: Krazati (adagrasib) · KRAS inhibitor
Condition: Thoracic

FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC

Drug: Lumakras (sotorasib) · KRAS inhibitor
Condition: Thoracic